168
Participants
Start Date
November 10, 2022
Primary Completion Date
November 10, 2027
Study Completion Date
November 10, 2027
Patient-specific adaptive therapy
Patients will start taking abiraterone or enzalutamide (AA/ENZ) daily. PSA will be measured every month as well as radiological evaluation by CT-scan and bone scan. Treatment will be continued until PSA has dropped \>50%. The treatment will then be paused. Once the PSA has risen again above the pretreatment baseline, treatment will be re-initiated. AA/ENZ will be stopped again after the PSA declines \>50% from the baseline. This will be continued until criteria for treatment failure are met (death by any cause or at least 2 out of 3 of the following events while on treatment: radiographic progression on CT-scan and/or bone scan, PSA progression or clinical progression).
Abiraterone acetate
Use of abiraterone or enzalutamide
Enzalutamide
Use of abiraterone or enzalutamide
RECRUITING
Chris O'Brien Lifehouse, Camperdown
RECRUITING
Genesis Care North Shore, St Leonards
RECRUITING
Sydney Adventist Hospital, Wahroonga
RECRUITING
Calvary Mater Newcastle, Newcastle
RECRUITING
Border Medical Oncology Research Unit / The Border Cancer Hospital, Albury
RECRUITING
Mater Hospital Brisbane, South Brisbane
RECRUITING
Royal Adelaide Hospital, Adelaide
RECRUITING
Fiona Stanly Hospital, Murdoch
RECRUITING
St George Hospital, Kogarah
RECRUITING
Sunshine Coast University Hospital, Birtinya
RECRUITING
ICON Cancer Centre, Adelaide
RECRUITING
Eastern Health Box Hill, Box Hill
RECRUITING
Radboud Univeristy Medical Centre, Nijmegen
RECRUITING
Spaarne Gasthuis, Hoofddorp
RECRUITING
Isala Ziekenhuis, Zwolle
RECRUITING
Groene Hart Ziekenhuis, Gouda
RECRUITING
Leids Universitair Medisch Centrum, Leiden
RECRUITING
Meander Medical Centre, Amersfoort
RECRUITING
University Medical Center Groningen, Groningen
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
OTHER
Anticancer Fund, Belgium
OTHER
Leiden University Medical Center
OTHER